All In Biotech

Drug Trial Radar · NCT00003088

Combination Chemotherapy in Treating Patients With Breast Cancer

A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer

Last checked: Nov 20, 2026Latest source record: Apr 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,005 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,005

Actual

Start

Sep 1997

Primary completion

Apr 2003

Study completion Jun 2003

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 6, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy consisting of either doxorubicin, cyclophosphamide, or paclitaxel given at different times with that of combination chemotherapy consisting of doxorubicin plus cyclophosphamide followed by paclitaxel in treating women with stage II or stage IIIA breast cancer.

Conditions

  • Breast Cancer

Interventions

  • cyclophosphamideDrug

    given IV

  • doxorubicin hydrochlorideDrug

    given IV

  • paclitaxelDrug

    given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survivalTime frame: 4 years

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • CCOP - Scottsdale Oncology Program

    Scottsdale, Arizona

  • CCOP - Illinois Oncology Research Association

    Peoria, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • CCOP - Cedar Rapids Oncology Project

    Cedar Rapids, Iowa

  • CCOP - Iowa Oncology Research Association

    Des Moines, Iowa

  • Siouxland Hematology-Oncology

    Sioux City, Iowa

  • CCOP - Ochsner

    New Orleans, Louisiana

  • CCOP - Ann Arbor Regional

    Ann Arbor, Michigan

  • CCOP - Duluth

    Duluth, Minnesota

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • CentraCare Clinic

    Saint Cloud, Minnesota

  • CCOP - Missouri Valley Cancer Consortium

    Omaha, Nebraska

  • Quain & Ramstad Clinic, P.C.

    Bismarck, North Dakota

  • CCOP - Merit Care Hospital

    Fargo, North Dakota

  • Altru Health Systems

    Grand Forks, North Dakota

  • CCOP - Toledo Community Hospital Oncology Program

    Toledo, Ohio

  • Rapid City Regional Hospital

    Rapid City, South Dakota

  • CCOP - Sioux Community Cancer Consortium

    Sioux Falls, South Dakota

  • Saskatchewan Cancer Agency

    Regina, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.